{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:10:16Z","timestamp":1778821816871,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015278","name":"Pfizer Healthcare Ireland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015278","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017614","name":"Arrien Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020189","name":"John and Mary Tu Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["5P42ES010337"],"award-info":[{"award-number":["5P42ES010337"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["5UL1TR001442"],"award-info":[{"award-number":["5UL1TR001442"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["CA170674P2"],"award-info":[{"award-number":["CA170674P2"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["K23DK119460"],"award-info":[{"award-number":["K23DK119460"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["DK079337"],"award-info":[{"award-number":["DK079337"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K23DK119460"],"award-info":[{"award-number":["K23DK119460"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["P30DK120515"],"award-info":[{"award-number":["P30DK120515"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK106419"],"award-info":[{"award-number":["R01DK106419"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.cct.2021.106330","type":"journal-article","created":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T20:35:55Z","timestamp":1614026155000},"page":"106330","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["RAMIC: Design of a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of ramipril in patients with COVID-19"],"prefix":"10.1016","volume":"103","author":[{"given":"Veeral","family":"Ajmera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wesley K.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davey M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravindra L.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaishal","family":"Tolia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishna","family":"Sriram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A.","family":"Insel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Summer","family":"Collier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Richards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2021.106330_bb0005","author":"WHO, WHO Coronavirus Disease (COVID-19) Dashboard"},{"issue":"19","key":"10.1016\/j.cct.2021.106330_bb0010","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 - preliminary report","volume":"383","author":"Beigel","year":"2020","journal-title":"New England J. Med."},{"key":"10.1016\/j.cct.2021.106330_bb0015","article-title":"Dexamethasone in hospitalized patients with Covid-19 - preliminary report","author":"Horby","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.cct.2021.106330_bb0020","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for Covid-19 - interim WHO solidarity trial results","volume":"384","author":"Pan","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.cct.2021.106330_bb0025","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention","volume":"323","author":"Wu","year":"2020","journal-title":"Jama"},{"issue":"20","key":"10.1016\/j.cct.2021.106330_bb0030","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","volume":"111","author":"Ferrario","year":"2005","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.cct.2021.106330_bb0035","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.12573","article-title":"Perinatally administered losartan augments renal ACE2 expression but not cardiac or renal mas receptor in spontaneously hypertensive rats","volume":"19","author":"Klimas","year":"2015","journal-title":"J. Cell. Mol. Med."},{"issue":"2","key":"10.1016\/j.cct.2021.106330_bb0040","doi-asserted-by":"crossref","DOI":"10.1097\/HJH.0b013e32834f04b6","article-title":"Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications","volume":"30","author":"Soro-Paavonen","year":"2012","journal-title":"J. Hypertens."},{"issue":"7807","key":"10.1016\/j.cct.2021.106330_bb0045","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2179-y","article-title":"Structural basis of receptor recognition by SARS-CoV-2","volume":"581","author":"Shang","year":"2020","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.cct.2021.106330_bb0050","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1001\/jama.2020.11301","article-title":"Association of Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality","volume":"324","author":"Fosb\u00f8l","year":"2020","journal-title":"JAMA"},{"issue":"25","key":"10.1016\/j.cct.2021.106330_bb0055","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2006923","article-title":"Renin-angiotensin-aldosterone system blockers and the risk of Covid-19","volume":"382","author":"Mancia","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.cct.2021.106330_bb0060","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2008975","article-title":"Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19","volume":"382","author":"Reynolds","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.cct.2021.106330_bb0065","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/cpt.1863","article-title":"Risks of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence","volume":"108","author":"Sriram","year":"2020","journal-title":"Clin. Pharmacol. & Ther."},{"issue":"8","key":"10.1016\/j.cct.2021.106330_bb0070","doi-asserted-by":"crossref","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury","volume":"11","author":"Kuba","year":"2005","journal-title":"Nat. Med."},{"issue":"22","key":"10.1016\/j.cct.2021.106330_bb0075","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.0711241105","article-title":"Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry","volume":"105","author":"Haga","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.cct.2021.106330_bb0080","doi-asserted-by":"crossref","DOI":"10.1007\/s00134-020-05985-9","article-title":"Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target","volume":"46","author":"Zhang","year":"2020","journal-title":"Intensive Care Med."},{"issue":"21","key":"10.1016\/j.cct.2021.106330_bb0085","doi-asserted-by":"crossref","first-page":"4825","DOI":"10.1111\/bph.15082","article-title":"A hypothesis for pathobiology and treatment of COVID-19: the centrality of ACE1\/ACE2 imbalance","volume":"177","author":"Sriram","year":"2020","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.cct.2021.106330_bb0090","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1161\/HYPERTENSIONAHA.120.15572","article-title":"Decreased mortality of COVID-19 with renin-angiotensin-aldosterone system inhibitors therapy in patients with hypertension: a meta-analysis","volume":"76","author":"Guo","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.cct.2021.106330_bb0095","article-title":"Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID-19, inflammation level, severity, and death in patients with COVID-19: A rapid systematic review and meta-analysis","author":"Liu","year":"2020","journal-title":"Clin. Cardiol."},{"issue":"10","key":"10.1016\/j.cct.2021.106330_bb0100","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11883-020-00880-6","article-title":"Effect of renin-angiotensin-aldosterone system inhibitors in patients with COVID-19: a systematic review and meta-analysis of 28,872 patients","volume":"22","author":"Baral","year":"2020","journal-title":"Curr. Atheroscler. Rep."},{"issue":"6","key":"10.1016\/j.cct.2021.106330_bb0105","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/BF00193704","article-title":"Pharmacokinetics, pharmacodynamics and bioavailability of the ACE inhibitor ramipril","volume":"47","author":"Van Griensven","year":"1995","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.cct.2021.106330_bb0110","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, Ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.cct.2021.106330_bb0115","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.amjhyper.2007.02.006","article-title":"Differential effects of ramipril on ambulatory blood pressure in African Americans and Caucasians","volume":"20","author":"Moran","year":"2007","journal-title":"Am. J. Hypertens."},{"issue":"12","key":"10.1016\/j.cct.2021.106330_bb0120","article-title":"Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin ii receptor blockers with mortality among patients with hypertension hospitalized with COVID-19","volume":"126","author":"Zhang","year":"2020","journal-title":"Circ. Res."},{"issue":"47","key":"10.1016\/j.cct.2021.106330_bb0125","doi-asserted-by":"crossref","first-page":"29274","DOI":"10.1073\/pnas.2009875117","article-title":"Targeting the renin-angiotensin signaling pathway in COVID-19: unanswered questions, opportunities, and challenges","volume":"117","author":"Sriram","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714421000665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714421000665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:25:56Z","timestamp":1778819156000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714421000665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":25,"alternative-id":["S1551714421000665"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2021.106330","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RAMIC: Design of a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of ramipril in patients with COVID-19","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2021.106330","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106330"}}